Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 27
Filtrar
1.
Zhonghua Gan Zang Bing Za Zhi ; 28(5): 434-440, 2020 May 20.
Artigo em Chinês | MEDLINE | ID: mdl-32536061

RESUMO

Objective: To compare the economic characteristics of the four artificial liver models [plasma exchange, half-dose plasma exchange combined with double plasma adsorption (DPMAS), pre-equal amount of plasma exchange followed by DPMAS, and pre-DPMAS followed by equal amount of plasma exchange] in the treatment of liver failure. Methods: A decision tree model was established with the Treeage pro 2011 software. The cost-effectiveness ratio and incremental cost-effectiveness value of four different treatment modalities were calculated and compared in patients with liver failure at early, mid and late stages, respectively. The sensitivity analysis of the model was performed using data from the preliminary research results of these groups. Results: The cost-effectiveness ratio and incremental cost-effectiveness value of patients treated with artificial liver therapy with half-dose plasma exchange combined with DPAMS plan in early stage liver failure were 89 547.79 and 34 665.34, which was lower than per capita GDP, so the increased cost had cost-effective advantages. In the middle and late stage of liver failure, the cost-effectiveness ratio and incremental cost-effectiveness value of pre-DPMAS followed by equal plasma exchange plan was 122 865.5 and 284 334.97, and 70 744.55 and 75 299.48, respectively, which was less than three times of per capita GDP. The increased cost was acceptable and had economic advantages. The sensitivity analysis results showed that the basic analysis results were reliable. Conclusion: Half-dose plasma exchange combined with DPAMS plan is the most cost-effective treatment for early liver failure, while pre-DPMAS followed by equal plasma exchange plan is the most economical treatment for mid and late stage liver failure.


Assuntos
Falência Hepática , Fígado Artificial , Troca Plasmática , Adsorção , Análise Custo-Benefício , Humanos , Falência Hepática/economia , Falência Hepática/terapia , Troca Plasmática/economia
2.
J Viral Hepat ; 25(8): 945-951, 2018 08.
Artigo em Inglês | MEDLINE | ID: mdl-29478258

RESUMO

Hepatocellular carcinoma (HCC) is a serious complication of hepatitis C virus (HCV) infection. Sustained virologic response (SVR) for HCV is associated with a reduction in cirrhosis, HCC and mortality and their associated costs. Japanese HCV patients are older with higher prevalence of HCC. Here we used a decision-analytic Markov model to estimate the economic benefit of HCV cure by reducing HCC and DCC burden in Japan. A cohort of 10 000 HCV genotype 1b (GT1b) Japanese patients was modelled with a hybrid decision tree and Markov state-transition model capturing natural history of HCV over a lifetime horizon. Treatment options were approved all-oral direct-acting anti-virals (DAAs) vs no treatment. Treatment efficacy was based on clinical trials and transition rates and costs obtained from Japan-specific data. Cases of HCC, decompensated cirrhosis (DCC) and quality-adjusted life years (QALYs) were projected for patients treated with DAAs vs NT. QALYs were monetized using a willingness-to-pay threshold of ¥4-to-¥6 million. Incremental savings with treatment were calculated by adding the projected cost of complications avoided to the monetized gains in QALYs. The model showed that DAA treatment vs no treatment, reduces 2057 cases of HCC and 1478 cases of decompensated cirrhosis and saves ¥850 446.73 and ¥338 229.90 per patient (ppt). Additionally, treatment can lead to additional 2.64 QALYs gained per patient. The indirect economic gains associated with treatment-related QALY improvements were ¥10 576 000, ¥13 220 000 and ¥15 864 000 ppt (willingness-to-pay thresholds of ¥4 million, ¥5 million and ¥6 million). Total economic savings of treatment with DAAs (vs no treatment) was ¥7 526 372.63, ¥10 170 372.63 and ¥12 814 372.63, at these different willingness-to-pay thresholds. In conclusion treatment of HCV GT1b with all-oral DAAs in Japan can lead to significant direct and indirect savings related to avoidance of HCC and DCC.


Assuntos
Antivirais/uso terapêutico , Carcinoma Hepatocelular/prevenção & controle , Custos e Análise de Custo , Hepatite C Crônica/complicações , Hepatite C Crônica/tratamento farmacológico , Cirrose Hepática/prevenção & controle , Falência Hepática/prevenção & controle , Antivirais/economia , Carcinoma Hepatocelular/economia , Carcinoma Hepatocelular/epidemiologia , Estudos de Coortes , Hepatite C Crônica/epidemiologia , Humanos , Japão/epidemiologia , Cirrose Hepática/economia , Cirrose Hepática/epidemiologia , Falência Hepática/economia , Falência Hepática/epidemiologia , Prevalência , Anos de Vida Ajustados por Qualidade de Vida
3.
BMC Palliat Care ; 16(1): 68, 2017 Dec 08.
Artigo em Inglês | MEDLINE | ID: mdl-29216873

RESUMO

BACKGROUND: Community-based palliative care is associated with reduced hospital costs for people dying from cancer. It is unknown if reduced hospital costs are universal across multiple life-limiting conditions amenable to palliative care. The aim of this study was to determine if community-based palliative care provided to people dying from non-cancer conditions was associated with reduced hospital costs in the last year of life and how this compared with people dying from cancer. METHOD: A retrospective population-based cohort study of all decedents in Western Australia who died January 2009 to December 2010 from a life-limiting condition considered amenable to palliative care. Hospital costs were assigned to each day of the last year of life for each decedent with a zero cost applied to days not in hospital. Day-specific hospital costs averaged over all decedents (cohort averaged) and decedents in hospital only (inpatient averaged) were estimated. Two-part models and generalised linear models were used. RESULTS: The cohort comprised 12,764 decedents who, combined, spent 451,236 (9.7%) days of the last year of life in hospital. Overall, periods of time receiving community-based specialist palliative care were associated with a 27% decrease from A$112 (A$110-A$114) per decedent per day to $A82 (A$78-A$85) per decedent per day of CA hospital costs. Community-based specialist palliative care was also associated a reduction of inpatient averaged hospital costs of 9% (7%-10%) to A$1030 per hospitalised decedent per day. Hospital cost reductions were observed for decedents with organ failures, chronic obstructive pulmonary disease, Alzheimer's disease, Parkinson's disease and cancer but not for motor neurone disease. Cost reductions associated with community-based specialist palliative care were evident 4 months before death for decedents with cancer and by one to 2 months before death for decedents dying from other conditions. CONCLUSION: Community-based specialist palliative care was associated with hospital cost reductions across multiple life-limiting conditions.


Assuntos
Custos Hospitalares/estatística & dados numéricos , Cuidados Paliativos/normas , Saúde Pública/economia , Idoso , Idoso de 80 Anos ou mais , Doença de Alzheimer/economia , Doença de Alzheimer/terapia , Estudos de Coortes , Custos e Análise de Custo , Feminino , Insuficiência Cardíaca/economia , Insuficiência Cardíaca/terapia , Custos Hospitalares/normas , Humanos , Falência Hepática/economia , Falência Hepática/terapia , Masculino , Pessoa de Meia-Idade , Cuidados Paliativos/economia , Cuidados Paliativos/métodos , Doença de Parkinson/economia , Doença de Parkinson/terapia , Doença Pulmonar Obstrutiva Crônica/economia , Doença Pulmonar Obstrutiva Crônica/terapia , Insuficiência Renal/economia , Insuficiência Renal/terapia , Estudos Retrospectivos , Austrália Ocidental , Recursos Humanos
4.
Clin Transplant ; 31(5)2017 05.
Artigo em Inglês | MEDLINE | ID: mdl-28235131

RESUMO

On June 18, 2013, the United Network for Organ Sharing (UNOS) instituted a change in the liver transplant allocation policy known as "Share 35." The goal was to decrease waitlist mortality by increasing regional sharing of livers for patients with a model for end-stage liver disease (MELD) score of 35 or above. Several studies have shown Share 35 successful in reducing waitlist mortality, particularly in patients with high MELD. However, the MELD score at transplant has increased, resulting in sicker patients, more complications, and longer hospital stays. Our study aimed to explore factors, along with Share 35, that may affect the cost of liver transplantation. Our results show Share 35 has come with significantly increased cost to transplant centers across the nation, particularly in regions 2, 5, 10, and 11. Region 5 was the only region with a median MELD above 35 at transplant, and cost was significantly higher than other regions. Several other recipient factors had changes with Share 35 that may significantly affect the cost of liver transplant. While access to transplantation for the sickest patients has improved, it has come at a cost and regional disparities remain. Financial implications with proposed allocation system changes must be considered.


Assuntos
Falência Hepática/economia , Transplante de Fígado/economia , Doadores de Tecidos , Obtenção de Tecidos e Órgãos/economia , Obtenção de Tecidos e Órgãos/normas , Listas de Espera , Feminino , Seguimentos , Humanos , Falência Hepática/cirurgia , Masculino , Pessoa de Meia-Idade , Prognóstico
5.
Am J Transplant ; 16(1): 287-91, 2016 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-26372681

RESUMO

The Share 35 policy for organ allocation, which was adopted in June 2013, allocates livers regionally for candidates with Model for End-Stage Liver Disease scores of 35 or greater. The authors analyzed the costs resulting from the increased movement of allografts related to this new policy. Using a sample of nine organ procurement organizations, representing 17% of the US population and 19% of the deceased donors in 2013, data were obtained on import and export costs before Share 35 implementation (June 15, 2012, to June 14, 2013) and after Share 35 implementation (June 15, 2013, to June 14, 2014). Results showed that liver import rates increased 42%, with an increased cost of 51%, while export rates increased 112%, with an increased cost of 127%. When the costs of importing and exporting allografts were combined, the total change in costs for all nine organ procurement organizations was $11 011 321 after Share 35 implementation. Extrapolating these costs nationally resulted in an increased yearly cost of $68 820 756 by population or $55 056 605 by number of organ donors. Any alternative allocation proposal needs to account for the financial implications to the transplant infrastructure.


Assuntos
Custos e Análise de Custo , Doença Hepática Terminal/prevenção & controle , Falência Hepática/economia , Transplante de Fígado/economia , Obtenção de Tecidos e Órgãos/economia , Humanos , Falência Hepática/diagnóstico , Falência Hepática/cirurgia , Prognóstico , Doadores de Tecidos , Listas de Espera
6.
South Med J ; 108(11): 682-7, 2015 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-26539950

RESUMO

OBJECTIVES: Patients with cirrhosis have a high rate of 30-day hospital readmission that affects their quality of life and contributes to increased healthcare-related costs. The aim of our study was to identify frequency, predictors, and preventable causes of hospital readmissions among patients with decompensated cirrhosis. METHODS: We retrospectively reviewed electronic medical records of all patients with a confirmed diagnosis of decompensated cirrhosis admitted to Dayton VA Medical Center between 2009 and 2013. Demographics, clinical factors, laboratory values, and outcomes were recorded. Univariate analysis was performed using independent samples t tests and Wilcoxon rank sums tests for continuous variables and χ(2) or Fisher exact tests for categorical variables. A multiple logistic regression analysis was performed for variables found to be significant by univariate analysis to predict the risk factors for 30-day readmission. A detailed chart review was conducted for all patients readmitted within 30 days by a single gastroenterologist to identify the reason for readmission and to decide whether any of these readmissions were preventable. RESULTS: The 30-day readmission rate for decompensated cirrhotic patients was 27.03%. The risk factors for 30-day readmission were higher body mass index (BMI), lower body temperature, higher blood urea nitrogen, higher creatinine, more cirrhosis-related complications, and more readmissions per year per univariate analysis. Multivariable analysis revealed only BMI as a significant predictor of 30-day readmission (P = 0.023). A total of 36.7% of 30-day readmissions were possibly preventable. CONCLUSIONS: The independent variable that predicted 30-day readmission in patients with decompensated cirrhosis was higher BMI. Approximately one-third of 30-day readmissions were possibly preventable. These findings support the need to develop specific interventions for disease management to improve patient care and save on extraneous healthcare costs.


Assuntos
Tempo de Internação/estatística & dados numéricos , Cirrose Hepática/mortalidade , Falência Hepática/mortalidade , Alta do Paciente/estatística & dados numéricos , Readmissão do Paciente/estatística & dados numéricos , Idoso , Índice de Massa Corporal , Diabetes Mellitus Tipo 2/mortalidade , Dislipidemias/mortalidade , Feminino , Custos de Cuidados de Saúde , Humanos , Tempo de Internação/economia , Cirrose Hepática/diagnóstico , Cirrose Hepática/economia , Cirrose Hepática/etiologia , Cirrose Hepática/terapia , Falência Hepática/diagnóstico , Falência Hepática/economia , Falência Hepática/etiologia , Falência Hepática/terapia , Masculino , Sistemas Computadorizados de Registros Médicos , Síndrome Metabólica/mortalidade , Pessoa de Meia-Idade , Obesidade/mortalidade , Alta do Paciente/economia , Readmissão do Paciente/economia , Prevalência , Estudos Retrospectivos , Medição de Risco , Fatores de Risco , Índice de Gravidade de Doença , Fatores de Tempo , Estados Unidos/epidemiologia
7.
Liver Transpl ; 21(7): 897-903, 2015 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-25891165

RESUMO

Because of a persistent discrepancy between the demand for liver transplantation (LT) and the supply of deceased donor organs, there is an interest in increasing living donation rates at centers trained in this method of transplantation. We examined a large socioeconomically heterogeneous cohort of patients listed for LT to identify recipient factors associated with living donation. We retrospectively reviewed 491 consecutive patients who were listed for LT at our center over a 24-month period. Demographic, medical, and socioeconomic data were extracted from electronic records and compared between those who had a potential living donor (LD) volunteer for assessment and those who did not; 245 patients (50%) had at least 1 potential LD volunteer for assessment. Multivariate logistic regression analysis identified that patients with a LD were more likely to have Child-Pugh C disease (odds ratio [OR], 2.44; P = 0.02), and less likely to be older (OR, 0.96; P = 0.002), single (OR, 0.34; P = 0.006), divorced (OR, 0.53; P = 0.03), immigrants (OR, 0.38; P = 0.049), or from the lowest income quintile (OR, 0.44; P = 0.02). In conclusion, this analysis has identified several factors associated with access to living donation. More research is warranted to define and overcome barriers to living donor liver transplantation through targeted interventions in underrepresented populations.


Assuntos
Falência Hepática/cirurgia , Transplante de Fígado/métodos , Doadores Vivos , Adulto , Idoso , Doenças Autoimunes/cirurgia , Colestase/cirurgia , Coleta de Dados , Feminino , Humanos , Hepatopatias/cirurgia , Falência Hepática/economia , Falência Hepática/epidemiologia , Masculino , Pessoa de Meia-Idade , Análise Multivariada , América do Norte , Razão de Chances , Seleção de Pacientes , Estudos Retrospectivos , Classe Social , Inquéritos e Questionários
8.
Transplantation ; 98(11): 1226-35, 2014 Dec 15.
Artigo em Inglês | MEDLINE | ID: mdl-25119126

RESUMO

BACKGROUND: Despite improvement in surgical technique and medical management of liver transplant recipients, biliary complications remain a frequent cause of posttransplant morbidity and graft loss. Biliary complications require potentially expensive interventions including radiologic procedures and surgical revisions. METHODS: A national data set linking transplant registry and Medicare claims data for 12,803 liver transplant recipients was developed to capture information on complications, treatments, and associated direct medical costs up to 3 years after transplantation. RESULTS: Biliary complications were more common in recipients of donation after cardiac death compared to donation after brain death allografts (23% vs. 19% P<0.001). Among donation after brain death recipients, biliary complications were associated with $54,699 (95% confidence interval [CI], $49,102 to $60,295) of incremental spending in the first year after transplantation and $7,327 in years 2 and 3 (95% CI, $4,419-$10,236). Biliary complications in donation after cardiac death recipients independently increased spending by $94,093 (95% CI, $64,643-$124,542) in the first year and $12,012 (95% CI, $-1,991 to $26,016) in years 2 and 3. CONCLUSION: This national study of biliary complications demonstrates the significant economic impact of this common perioperative complication and suggests a potential target for quality of care improvements.


Assuntos
Doenças Biliares/etiologia , Falência Hepática/cirurgia , Transplante de Fígado/efeitos adversos , Transplante de Fígado/economia , Adulto , Idoso , Doenças Biliares/economia , Morte Encefálica , Estudos de Coortes , Morte , Feminino , Humanos , Revisão da Utilização de Seguros , Falência Hepática/complicações , Falência Hepática/economia , Masculino , Medicare , Pessoa de Meia-Idade , Análise Multivariada , Complicações Pós-Operatórias , Modelos de Riscos Proporcionais , Qualidade da Assistência à Saúde , Resultado do Tratamento , Estados Unidos , Adulto Jovem
9.
Am J Transplant ; 14(1): 70-8, 2014 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-24165015

RESUMO

Previous economic analyses of liver transplantation have focused on the cost of the transplant and subsequent care. Accurate characterization of the pretransplant costs, indexed to severity of illness, is needed to assess the economic burden of liver disease. A novel data set linking Medicare claims with transplant registry data for 15,710 liver transplant recipients was used to determine average monthly waitlist spending (N = 249,434 waitlist months) using multivariable linear regression models to adjust for recipient characteristics including Model for End-Stage Liver Disease (MELD) score. Characteristics associated with higher spending included older age, female gender, hepatocellular carcinoma, diabetes, hypertension and increasing MELD score (p < 0.05 for all). Spending increased exponentially with severity of illness: expected monthly spending at a MELD score of 30 was 10 times higher than at MELD of 20 ($22,685 vs. $2030). Monthly spending within MELD strata also varied geographically. For candidates with a MELD score of 35, spending varied from $19,548 (region 10) to $36,099 (region 7). Regional variation in waitlist costs may reflect the impact of longer waiting times on greater pretransplant hospitalization rates among high MELD score patients. Reducing the number of high MELD waitlist patients through improved medical management and novel organ allocation systems could decrease total spending for end-stage liver care.


Assuntos
Doença Hepática Terminal/economia , Hospitalização/economia , Transplante de Fígado/economia , Adulto , Carcinoma Hepatocelular/economia , Carcinoma Hepatocelular/cirurgia , Doença Hepática Terminal/cirurgia , Feminino , Humanos , Falência Hepática/economia , Falência Hepática/cirurgia , Neoplasias Hepáticas/economia , Neoplasias Hepáticas/cirurgia , Masculino , Medicare , Pessoa de Meia-Idade , Sistema de Registros , Índice de Gravidade de Doença , Obtenção de Tecidos e Órgãos/economia , Estados Unidos , Listas de Espera/mortalidade
10.
Transplant Proc ; 45(1): 259-64, 2013.
Artigo em Inglês | MEDLINE | ID: mdl-23375312

RESUMO

BACKGROUND: There are limited data on length of stay (LOS) following liver transplantation (LT), yet this is an important health services metric that directly correlates with early post-LT health care costs. The primary objective of this study was to examine the relationship between early allograft dysfunction (EAD) and LOS after LT. The secondary objective was to identify additional recipient, donor, and operative factors associated with LOS. METHODS: Adult patients undergoing primary LT over a 32-month period were prospectively examined at a single center. Subjects fulfilling standard criteria for EAD were compared with those not meeting the definition. Variables associated with increased LOS on ordinal logistic regression were identified. RESULTS: Subjects with EAD had longer mean hospital LOS than those without (42.5 ± 38.9 days vs 27.4 ± 31 days; P = .003). Subjects with EAD also had longer mean intensive care LOS (8.61 ± 10.28 days vs 5.45 ± 11.6 days; P = .048). Additional factors significantly associated with LOS included Model for End-Stage Liver Disease (MELD) score, recipient location before LT, and postoperative surgical complications. CONCLUSIONS: EAD is associated with longer hospitalization after LT. MELD score, preoperative recipient location, and postoperative complications were significantly associated with LOS. From a cost-containment perspective, these findings have implications on resource allocation.


Assuntos
Falência Hepática/cirurgia , Transplante de Fígado/métodos , Adulto , Idoso , Feminino , Sobrevivência de Enxerto , Hospitalização , Humanos , Tempo de Internação/economia , Falência Hepática/economia , Transplante de Fígado/economia , Masculino , Pessoa de Meia-Idade , Ontário , Complicações Pós-Operatórias/economia , Estudos Prospectivos , Garantia da Qualidade dos Cuidados de Saúde , Análise de Regressão , Índice de Gravidade de Doença , Fatores de Tempo , Doadores de Tecidos , Transplante Homólogo/economia , Resultado do Tratamento
11.
Ther Umsch ; 68(12): 707-13, 2011 Dec.
Artigo em Alemão | MEDLINE | ID: mdl-22139986

RESUMO

During the past two decades, orthotopic liver transplantation (OLT) emerged to the treatment of choice for patients with end-stage liver disease. In Switzerland, about 100 liver transplantations are performed every year, while the shortage of cadaveric organs considerably outmatches the demand. Common indications for OLT include cirrhosis due to alcoholic liver disease or chronic viral hepatitis related to hepatitis B or C, and hepatocellular carcinoma. With the advent of the new allocation policy in Switzerland in 2007, patients listed for OLT are mainly stratified based on the Model of End-stage Liver Disease (MELD) score. Using a patient's laboratory values for serum bilirubin, serum creatinin, and the international normalized ratio for prothrombin time (INR), the MELD score accurately predicts three-month mortality among patients on the waiting list. Compared to the pre-MELD era, patients with significantly higher MELD scores undergo transplantation which leads in turn to more complications and higher costs yet with a comparable outcome. Timely referral of potential candidates to a transplant center is crucial since thorough evaluation to rule out contraindications such as uncontrolled infection, extrahepatic malignancy or advanced cardiopulmonary disease is essential. Taken together, every patient presenting with acute liver failure, decompensated cirrhosis or suspected hepatocellular carcinoma should be evaluated in a center with liver transplantation capability.


Assuntos
Falência Hepática/cirurgia , Transplante de Fígado/legislação & jurisprudência , Transplante de Fígado/métodos , Seleção de Pacientes , Análise Custo-Benefício , Seguimentos , Sobrevivência de Enxerto , Necessidades e Demandas de Serviços de Saúde , Humanos , Cobertura do Seguro/economia , Falência Hepática/economia , Falência Hepática/etiologia , Testes de Função Hepática , Transplante de Fígado/economia , Transplante de Fígado/mortalidade , Complicações Pós-Operatórias/economia , Complicações Pós-Operatórias/mortalidade , Taxa de Sobrevida , Suíça , Doadores de Tecidos/provisão & distribuição
12.
Liver Transpl ; 17(11): 1333-43, 2011 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-21770017

RESUMO

Cost issues in liver transplantation (LT) have received increasing attention, but the cost-utility is rarely calculated. We compared costs per quality-adjusted life year (QALY) from the time of placement on the LT waiting list to 1 year after transplantation for 252 LT patients and to 5 years after transplantation for 81 patients. We performed separate calculations for chronic liver disease (CLD), acute liver failure (ALF), and different Model for End-Stage Liver Disease (MELD) scores. For the estimation of QALYs, the health-related quality of life was measured with the 15D instrument. The median costs and QALYs after LT were €141,768 and 0.895 for 1 year and €177,618 and 3.960 for 5 years, respectively. The costs of the first year were 80% of the 5-year costs. The main cost during years 2 to 5 was immunosuppression drugs (59% of the annual costs). The cost/QALY ratio improved from €158,400/QALY at 1 year to €44,854/QALY at 5 years, and the ratio was more beneficial for CLD patients (€42,500/QALY) versus ALF patients (€63,957/QALY) and for patients with low MELD scores versus patients with high MELD scores. Although patients with CLD and MELD scores > 25 demonstrated markedly higher 5-year costs (€228,434) than patients with MELD scores < 15 (€169,541), the cost/QALY difference was less pronounced (€59,894/QALY and €41,769/QALY, respectively). The cost/QALY ratio for LT appears favorable, but it is dependent on the assessed time period and the severity of the liver disease.


Assuntos
Custos de Cuidados de Saúde/estatística & dados numéricos , Falência Hepática , Transplante de Fígado/economia , Transplante de Fígado/mortalidade , Qualidade de Vida , Anos de Vida Ajustados por Qualidade de Vida , Adulto , Colangite Esclerosante/economia , Colangite Esclerosante/mortalidade , Colangite Esclerosante/cirurgia , Análise Custo-Benefício/economia , Análise Custo-Benefício/estatística & dados numéricos , Custos de Medicamentos/estatística & dados numéricos , Feminino , Finlândia/epidemiologia , Humanos , Imunossupressores/economia , Cirrose Hepática Biliar/economia , Cirrose Hepática Biliar/mortalidade , Cirrose Hepática Biliar/cirurgia , Hepatopatias Alcoólicas/economia , Hepatopatias Alcoólicas/mortalidade , Hepatopatias Alcoólicas/cirurgia , Falência Hepática/economia , Falência Hepática/mortalidade , Falência Hepática/cirurgia , Masculino , Pessoa de Meia-Idade , Modelos Estatísticos
13.
Am J Transplant ; 11(4): 798-807, 2011 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-21401867

RESUMO

Liver transplantation has evolved over the past four decades into the most effective method to treat end-stage liver failure and one of the most expensive medical technologies available. Accurate understanding of the financial implication of recipient severity of illness is crucial to assessing the economic impact of allocation policies. A novel database of linked clinical data from the Organ Procurement and Transplantation Network with cost accounting data from the University HealthSystem Consortium was used to analyze liver transplant costs for 15,813 liver transplants. This data was then utilized to consider the economic impact of alternative allocation systems designed to increase sharing of liver allografts using simulation results. Transplant costs were strongly associated with recipient severity of illness as assessed by the MELD score (p < 0.0001); however, this relationship was not linear. Simulation analysis of the reallocation of livers from low MELD patients to high MELD using a two-tiered regional sharing approach (MELD 15/25) resulted in 88 fewer deaths annually at estimated cost of $17,056 per quality-adjusted life-year saved. The results suggest that broader sharing of liver allografts offers a cost-effective strategy to reduce the mortality from end stage liver disease.


Assuntos
Doença Hepática Terminal/prevenção & controle , Falência Hepática/economia , Transplante de Fígado/economia , Modelos Econômicos , Obtenção de Tecidos e Órgãos/economia , Adolescente , Adulto , Criança , Estudos de Coortes , Custos e Análise de Custo , Feminino , Humanos , Falência Hepática/diagnóstico , Falência Hepática/cirurgia , Masculino , Pessoa de Meia-Idade , Índice de Gravidade de Doença , Doadores de Tecidos , Adulto Jovem
14.
J Hepatobiliary Pancreat Sci ; 18(2): 184-9, 2011 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-20845048

RESUMO

BACKGROUND AND PURPOSE: Living donor liver transplantation (LDLT) is now a well established treatment modality for end-stage liver diseases, but the financial aspects of LDLT have not yet been fully investigated. The purpose of this study was to determine the overall direct cost of adult-adult LDLT in Japan and to identify the factors associated with the high cost. MATERIALS AND METHODS: The direct cost of initial admission for LDLT was determined in a retrospective analysis of data from hospital charts and databases. The records for 100 consecutive adults who underwent LDLT from January 2004 to February 2006 at our center were reviewed, and clinical and financial data of all recipients and donors were analyzed. RESULTS: The median direct total cost for LDLT was $82,017 (range $51,189-438,295). Of this, the median cost for donors was $15,011 (range $12,354-23,251). A multivariate stepwise logistic regression model for overall cost of transplantation revealed that donor age [odds ratio (OR) = 1.1, p = 0.02], acute renal failure (OR = 24, p = 0.007), and posttransplant plasma exchange (OR = 72, p = 0.01) were associated with higher cost. When the models were repeated with preoperative patient and donor factors alone, donor age (OR 1.1, p = 0.008) and model for end stage liver disease score (OR 1.2, p = 0.003) were associated with higher cost. CONCLUSIONS: Donor age, acute renal failure, and posttransplant plasma exchange were independent risk factors for the high cost of LDLT in Japan.


Assuntos
Custos Hospitalares/estatística & dados numéricos , Hospitais Universitários/economia , Falência Hepática/cirurgia , Transplante de Fígado/economia , Doadores Vivos , Adulto , Idoso , Custos e Análise de Custo , Feminino , Humanos , Falência Hepática/economia , Masculino , Pessoa de Meia-Idade , Estudos Retrospectivos , Tóquio , Adulto Jovem
15.
Liver Transpl ; 16(5): 668-77, 2010 May.
Artigo em Inglês | MEDLINE | ID: mdl-20440776

RESUMO

Organ allocation based on Model for End-Stage Liver Disease (MELD) resulted in decreased waiting list mortality in the United States. However, reports suggest an increase in resource utilization as a consequence of this. The aim of this study is to assess the correlation of MELD at transplant with post-liver transplant (LT) intensive care unit (ICU) costs. We assessed clinical and demographic variables of 402 adult patients who underwent LT at King's College Hospital, London, UK, between January 2000 and December 2003. ICU cost calculations were based on the therapeutic intervention scoring system (TISS). Graft quality was assessed using the donor risk index (DRI). Patients with a MELD score > 24 had significantly longer post-LT ICU stay (P < 0.0001) and total post-LT hospital stay (P = 0.008). In addition, they had significantly increased TISS scores, ICU cost, and need for renal replacement therapy (RRT) (P < 0.001). MELD score (by point) and MELD > 24 was associated with prolonged ICU stay (P = 0.004 and P = 0.005, respectively). On univariate analysis, etiology of alcohol-related liver disease (ALD), repeat LT, Budd-Chiari syndrome, and refractory ascites were associated with prolonged ICU stay. Using multivariate analysis, MELD > 24, refractory ascites, ALD and Budd-Chiari syndrome were associated with prolonged ICU stay. There was no association between using grafts with higher DRI and longer ICU stay, need for RRT, increased cost, or hospital survival on univariate analyses (P = not significant). Use of MELD as a method of organ allocation results in significant increase in ICU cost after LT. Using TISS as surrogate marker for ICU costs reveals that the cost implications are related to the need for RRT and prolonged ICU stay.


Assuntos
Hospitalização/economia , Unidades de Terapia Intensiva/economia , Falência Hepática/economia , Falência Hepática/cirurgia , Transplante de Fígado/economia , Modelos Econométricos , Feminino , Custos de Cuidados de Saúde , Humanos , Falência Hepática/mortalidade , Transplante de Fígado/mortalidade , Modelos Logísticos , Masculino , Pessoa de Meia-Idade , Análise Multivariada , Complicações Pós-Operatórias/economia , Terapia de Substituição Renal/economia , Fatores de Risco , Índice de Gravidade de Doença , Doadores de Tecidos , Obtenção de Tecidos e Órgãos/economia , Reino Unido/epidemiologia , Listas de Espera
18.
Langenbecks Arch Surg ; 394(6): 1047-56, 2009 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-19533168

RESUMO

PURPOSE: Postoperative liver failure (PLF) is a relatively frequent and life-threatening complication after extended liver resection. This study describes the economic burden of PLF from the hospitals' perspective and explores the role of liver function capacity. MATERIALS AND METHODS: Economic data of total costs and cost distribution were analyzed for 48 patients who had participated in a prospective study with the LiMAx test, a novel test for liver function capacity. For this population, detailed individual data were available. The economic data were analyzed and adjusted for relevant covariates. In addition, economic data of 916 patients who had undergone liver resection during 2005-2007 were retrieved from the hospitals' medical controlling office for comparison. RESULTS: A significant difference between the costs of patients with regular recovery (25,980 Euro [95% confidence interval (95%CI) = 9,559 to 42,401]) versus patients developing PLF (82,199 Euro [95%CI = 42,812 to 121,586]; p = 0.013) was observed. The mean additional costs of PLF were 56,219 Euro. An equivalent cost difference of mortality was obtained from the analysis of 916 patients. Patients developing PLF had a decreased LiMAx of 61 microg/kg/h compared to the regular group 122 microg/kg/h (p < 0.001) after surgery. Initial postoperative LiMAx and total costs revealed a linear correlation coefficient of r = -0.340 (p = 0.018). CONCLUSIONS: PLF is a very relevant medical and economic problem. Liver function capacity does not only predict PLF but also correlates with total costs in general.


Assuntos
Custos de Cuidados de Saúde , Hepatectomia/efeitos adversos , Falência Hepática/economia , Falência Hepática/etiologia , Adulto , Idoso , Estudos de Coortes , Feminino , Humanos , Falência Hepática/diagnóstico , Testes de Função Hepática , Masculino , Pessoa de Meia-Idade , Valor Preditivo dos Testes , Recuperação de Função Fisiológica , Estudos Retrospectivos , Resultado do Tratamento
19.
Aliment Pharmacol Ther ; 26(8): 1147-61, 2007 Oct 15.
Artigo em Inglês | MEDLINE | ID: mdl-17894657

RESUMO

BACKGROUND: Treatment options for hepatic encephalopathy have disparate risks and benefits. Non-absorbable disaccharides and neomycin are limited by uncertain efficacy and common dose-limiting side effects. In contrast, rifaximin is safe and effective in hepatic encephalopathy, but is more expensive. METHODS: We conducted a decision analysis to calculate the cost-effectiveness of six strategies in hepatic encephalopathy: (i) no hepatic encephalopathy treatment, (ii) lactulose monotherapy, (iii) lactitol monotherapy, (iv) neomycin monotherapy, (v) rifaximin monotherapy and (vi) up-front lactulose with crossover to rifaximin if poor response or intolerance of lactulose ('rifaximin salvage'). The primary outcome was cost per quality-adjusted life-year gained. RESULTS: Under base-case conditions, 'do nothing' was least effective and rifaximin salvage was most effective. Lactulose monotherapy was least expensive, and rifaximin monotherapy was most expensive. When balancing cost and effectiveness, lactulose monotherapy and rifaximin salvage dominated alternative strategies. Compared to lactulose monotherapy, rifaximin salvage cost an incremental US$2315 per quality-adjusted life-year-gained. The cost of rifaximin had to fall below US$1.03/tab in order for rifaximin monotherapy to dominate lactulose monotherapy. CONCLUSIONS: Rifaximin monotherapy is not cost-effective in the treatment of chronic hepatic encephalopathy at current average wholesale prices. However, a hybrid salvage strategy, reserving rifaximin for lactulose-refractory patients, may be highly cost-effective.


Assuntos
Análise Custo-Benefício , Fármacos Gastrointestinais/uso terapêutico , Encefalopatia Hepática/tratamento farmacológico , Lactulose/uso terapêutico , Falência Hepática/complicações , Transplante de Fígado , Rifamicinas/uso terapêutico , Feminino , Fármacos Gastrointestinais/economia , Fármacos Gastrointestinais/farmacologia , Encefalopatia Hepática/diagnóstico , Encefalopatia Hepática/economia , Hospitalização/economia , Humanos , Lactulose/economia , Lactulose/farmacologia , Falência Hepática/economia , Los Angeles , Masculino , Pessoa de Meia-Idade , Rifamicinas/economia , Rifamicinas/farmacologia , Rifaximina
20.
J Gastroenterol ; 41(10): 1005-10, 2006 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-17096070

RESUMO

BACKGROUND: The model for end-stage liver disease (MELD) is useful for assessing the recipients of liver transplants, namely, deceased-donor transplantation. The application of MELD for living donor liver transplantation (LDLT) is under investigation. Thus, the aim of this study was to analyze the impact of the MELD score in LDLT in Japan. METHODS: Seventeen adult cases of LDLT during 2001 to 2005 were enrolled. Indications for LDLT were primary biliary cirrhosis, seven; liver cirrhosis, two; hepatocellular carcinoma (HCC), three; metabolic liver disease, one; primary sclerosing cholangitis, two; Caroli's disease, one; and biliary atresia, one. Total medical charges during the operative periods were retrospectively evaluated. The united network of organ sharing (UNOS) modified was obtained using preoperative clinical data. RESULTS: The average medical expense of the 17 cases was approximately 97,901 US dollar. The UNOS-modified MELD score was 22.1. A statistically significant positive correlation was found between the MELD score and medical expense (P = 0.0086, rho = 0.657), and between the MELD score and the length of stay in the intensive care unit (ICU) (P = 0.0396, rho = 0.515). The cause of the liver disease leading to transplantation was not related to MELD score, medical expense, or length of ICU stay. CONCLUSIONS: Although not originally designed for the application to LDLT, the MELD score is useful for predicting medical expenses in LDLT. Similar to those of deceased-donor liver transplantation, the disadvantage of high medical expenses associated with a high MELD score allow consideration of an earlier elective operation in suitable cases.


Assuntos
Falência Hepática , Transplante de Fígado/economia , Doadores Vivos , Modelos Econômicos , Adulto , Custos e Análise de Custo , Feminino , Seguimentos , Humanos , Unidades de Terapia Intensiva/economia , Tempo de Internação/economia , Falência Hepática/diagnóstico , Falência Hepática/economia , Falência Hepática/cirurgia , Masculino , Pessoa de Meia-Idade , Estudos Retrospectivos , Índice de Gravidade de Doença
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA